Clinical and Translational Oncology

, Volume 9, Issue 8, pp 521–530 | Cite as

Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription

  • V. Cepero
  • B. García-Serrelde
  • V. Moneo
  • F. Blanco
  • A. M. González-Vadillo
  • A. Álvarez-Valdés
  • C. Navarro-Ranninger
  • A. CarneroEmail author
Research Articles



Enhanced removal of cisplatin-DNA adducts has been reported as one of main causesof cell resistance to cisplatin. This particular resistance mechanism may be circumvented by platinum complexes that bind differently to DNA. One line of work is focussed on trans platinum complexes, some of which exhibit antitumour activity similar to or even higher than that of their cis counterparts.


We synthesised new trans platinum complexes, trans-[PtCl2(cyclohexylamine) (dimethylamine)] and trans-[PtCl2(OH)2(cyclohexylamine) (dimethylamine)], previously evaluated as cytotoxic agents towards different cancer and normal cell lines. These trans platinum compounds were highly effective against a panel of tumoral cell lines either sensitive to or with acquired resistance to cisplatin.


In the present work we examined the mechanisms induced by these compounds to cause tumour cells toxicity. We have found that these compounds induced a complete blockade at the S phase of the cell cycle inhibiting total mRNA transcription and precluding p53 activation.


In contrast to other DNA-damaging agents, these compounds do not induce senescence-associated permanent arrest. Furthermore, only a small percentage of these cells enter into apoptosis, with most of the population dying by a necrosis-like mechanism.

Key words

Antitumour drugs Platinum anticancer drugs Transplatin Cytotoxic activity Cell cycle 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lippert B (1999) 30 years of cisplatin — chemistry and biochemistry of a leading anticancer drug. Verlag HCA, BaselGoogle Scholar
  2. 2.
    Giaccone G (2000) Clinical perspectives on platinum resistance. Drugs 59[Suppl]:4–9Google Scholar
  3. 3.
    Kelland LR, Farrell N (2000). Platinum-based drugs in cancer therapy. In: Teicher BA (ed.) Cancer drug discovery and development. Humana Press, Clifton, UKGoogle Scholar
  4. 4.
    Cohen SM, Lippard SJ (2001) Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67:93–130PubMedGoogle Scholar
  5. 5.
    Zamble BD, Lippard SJ (1995) Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20:435–439PubMedCrossRefGoogle Scholar
  6. 6.
    Trimmer EE, Essigmann JM (1999) Cisplatin. Essays Biochem 34:191–211PubMedGoogle Scholar
  7. 7.
    Brabec V, Kasparkova J (2002) Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updates 5:147–161CrossRefGoogle Scholar
  8. 8.
    Zhang CX, Lippard SJ (2003) New metal complexes as potential therapeutics. Curr Opin Chem Biol 7:481–489PubMedCrossRefGoogle Scholar
  9. 9.
    Heiger-Bernays WJ, Essigmann JM, Lippard SJ (1990) Effects of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. Biochemistry 29:8461–8466PubMedCrossRefGoogle Scholar
  10. 10.
    Farrell N, Kelland LR, Roberts JD, Van Beusichem M (1992) Activation of the trans geometry in platinum antitumor complexes. A survey of the cytotoxicity of trans complexes containing planar ligands in Murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res 52:5065–5072PubMedGoogle Scholar
  11. 11.
    Kelland LR, Barnard CF, Evans IG et al (1995) Synthesis and in vitro antitumor activity of a series of trans platinum antitumor complexes. J Med Chem 38:3016–3024PubMedCrossRefGoogle Scholar
  12. 12.
    Montero EI, Diaz S, Gonzalez-Vadillo AM et al (1999). Preparation and characterization of novel trans-[PtCl(2)(amine)(isopropylamine)] compounds: cytotoxic activity and apoptosis induction in ras-transformed cells. J Med Chem 42:4264–4268PubMedCrossRefGoogle Scholar
  13. 13.
    Natile G, Coluccia M (2001) Current status of trans-platinum compounds in cancer therapy. Coord Chem Rev 216–217:383–410CrossRefGoogle Scholar
  14. 14.
    Perez JM, Fuertes MA, Alonso C, Navarro-Ranninger C (2000) Current status of the development of trans-platinum antitumor drugs. Crit Rev Oncol Hematol 35:109–120PubMedCrossRefGoogle Scholar
  15. 15.
    Perez JM, Montero EI, Gonzalez AM et al (2000) X-ray structure of cytotoxic trans-[Pt-Cl(2)(dimethylamine)(isopropylamine)]: interstrand cross-link efficiency, DNA sequence specificity, and inhibition of the B-Z transition. J Med Chem 43:2411–2418PubMedCrossRefGoogle Scholar
  16. 16.
    Riccardi A, Meco D, Ferlini C et al (2001) In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma. Cancer Chemother Pharmacol 47:498–504PubMedCrossRefGoogle Scholar
  17. 17.
    Servidei T, Ferlini C, Riccardi A et al (2001). The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur J Cancer 37:930–938PubMedCrossRefGoogle Scholar
  18. 18.
    Van Beusichem M, Farrell N (1992) Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterisation and biological activity of complexes with planar ligands pyridine, N-methylimidazole, thiazole and quinoline. The crystal and molecular structure of trans-dichlorobis(thiazole)platinum(II). Inorg Chem 31:634–639CrossRefGoogle Scholar
  19. 19.
    Farrell N (1996) Current status of structure-activity relationships of platinum anticancer drugs. Activation of the trans geometry. Metal Ions Biol Sys 32:603–639Google Scholar
  20. 20.
    Zou Y, Van Houten B, Farrell N (1993) Ligand effects on platinum binding to DNA. A comparison of DNA binding properties for cis-and trans-[PtCl2(amine)2] (amine = NH3, pyridine). Biochemistry 32:9632–9638PubMedCrossRefGoogle Scholar
  21. 21.
    Brabec V (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Progr Nucleic Acid Res Mol Biol 71:1–68Google Scholar
  22. 22.
    Farrell N, Povirk LF, Dange Y et al (2004) Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells. Biochem Pharmacol 68:857–866PubMedCrossRefGoogle Scholar
  23. 23.
    Perez JM, Kelland LR, Montero EI et al (2003) Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[Pt-Cl(2)(OH)(2)(dimethylamine) (isopropylamine)]. Mol Pharmacol 63:933–944PubMedCrossRefGoogle Scholar
  24. 24.
    Bierbach U, Qu Y, Hambley TW et al (1999) Synthesis, structure, biological activity and DNA binding of platinum(II) complexes of the type trans-[PtCl2(NH3)L] (L = planar nitrogen base). Effect of L and cis/trans isomerism on sequence specificity and unwinding properties observed in globally platinated DNA. Inorg Chem 38:3535–3542PubMedCrossRefGoogle Scholar
  25. 25.
    Najajreh Y, Pérez JM, Navarro-Ranninger C, Gibson D (2002) Novel soluble cationic transdiaminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines. J Med Chem 45:5189–5195PubMedCrossRefGoogle Scholar
  26. 26.
    Barnard CFJ, Raynaud FY, Kelland LR (1999) In: Clarke MJ, Sadler PJ (eds) Metallopharmaceuticals I: DNA Interactions. Springer, Berlin, pp. 45Google Scholar
  27. 27.
    Kelland LR, Abel G, McKeage MJ et al (1993) Preclinical antitumor evaluation of bis-acetatoammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 53:2581–2586PubMedGoogle Scholar
  28. 28.
    González-Vadillo AM, Álvarez-Valdés A, Moneo V et al (2007) Structure-activity relationship of new trans platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death. J Inorg Biochem 101:551–558PubMedCrossRefGoogle Scholar
  29. 29.
    Moneo V, Serelde BG, Leal JF et al (2007) Levels of p27kip1 determine Aplidin sensitivity. Mol Cancer Ther 6:1310–1316PubMedCrossRefGoogle Scholar
  30. 30.
    Pucci B, Kasten M, Giordano A (2000) Cell cycle and apoptosis. Neoplasia 2:291–299PubMedCrossRefGoogle Scholar
  31. 31.
    Siddick ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265–7279CrossRefGoogle Scholar
  32. 32.
    Campisi J (2005) Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120:513–522PubMedCrossRefGoogle Scholar
  33. 33.
    Carnero A (2007) Cellular senescence as a target in cancer control. Curr Cancer Ther Rev 3:7–15CrossRefGoogle Scholar
  34. 34.
    Roninson IB, Broude EV, Chang BD (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4:303–313PubMedCrossRefGoogle Scholar
  35. 35.
    Carnero A, Blanco C, Blanco F et al (2003) Exploring cellular senescence as a tumor suppressor mechanism. Revista de Oncologia 5:249–265Google Scholar
  36. 36.
    Shay JW, Roninson IB (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23:2919–2933PubMedCrossRefGoogle Scholar
  37. 37.
    Wyllie AH (1993) Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer 67:205–208PubMedGoogle Scholar
  38. 38.
    Wyllie AH, Kerr JF, Currie AR (1980) Cell death: the significance of apoptosis. Int Rev Cytol 68:251–306PubMedCrossRefGoogle Scholar
  39. 39.
    Hickman JA (1992) Apoptosis induced by anticancer agents. Cancer Metastasis Rev 11:121–139PubMedCrossRefGoogle Scholar
  40. 40.
    Blanc C, Devereux QL, Krajewski S et al (2000) Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 60:4386–4390PubMedGoogle Scholar
  41. 41.
    Montero EI, Perez JM, Schwartz A et al (2002) Apoptosis induction and DNA interstrand crosslink formation by cytotoxic trans-[PtCl2(NH(CH3)2)(NHCH(CH3)2)]: cross-linking between d(G) and complementary d(C) within oligonucleotide duplexes. ChemBioChem 3:61–67PubMedCrossRefGoogle Scholar
  42. 42.
    Pantoja E, Gallipoli A, van Zutphen S et al (2006) In vitro antitumor activity and interaction with DNA model bases of cis-[PtCl2(iPram)(azole)] complexes and comparison with their trans analogues. Inorg Chim Acta 359:4335–4342CrossRefGoogle Scholar
  43. 43.
    Moneo V, Serelde BG, Fominaya J et al (2007) Extreme sensitivity to Yondelis(R) (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 100: 339–348PubMedCrossRefGoogle Scholar
  44. 44.
    Coluccia M, Nassi A, Boccarelli A et al (1999) In vitro antitumour activity and cellular pharmacological properties of the platinum-iminoether complex trans-[PtCl2[E-HN=C(OMe)Me]2]. Int J Oncol 15:1039–1044PubMedGoogle Scholar
  45. 45.
    Coluccia M, Nassi A, Boccarelli A et al (1999) In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands. J Inorg Biochem 77:31–35PubMedCrossRefGoogle Scholar
  46. 46.
    Coluccia M, Nassi A, Loseto F et al (1993) A trans-platinum complex showing higher antitumor activity than the cis congeners. J Med Chem 36:510–512PubMedCrossRefGoogle Scholar
  47. 47.
    Ormerod MG, O’Neill C, Robertson D et al (1996). cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37:463–471PubMedCrossRefGoogle Scholar
  48. 48.
    O’Neill CF, Ormerod MG, Robertson D et al (1996) Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine) dihydroxodichloroplatinum(IV) complex. Br J Cancer 74:1037–1045PubMedGoogle Scholar
  49. 49.
    Orlandi L, Colella G, Bearzatto A et al (2001) Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: interference with cell cycle progression and induction of apoptosis. Eur J Cancer 37:649–659PubMedCrossRefGoogle Scholar
  50. 50.
    Pinto AL, Lippard SJ (1985) Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 780:167–180PubMedGoogle Scholar
  51. 51.
    O’Connor PM, Fan S (1996) DNA damage checkpoints: implications for cancer therapy. Prog Cell Cycle Res 2:165–173PubMedGoogle Scholar
  52. 52.
    Eliopoulos AG, Kerr DJ, Herod J et al (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11:1217–1228PubMedGoogle Scholar
  53. 53.
    Hagopian GS, Mills GB, Khokhar AR et al (1999) Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res 5:655–663PubMedGoogle Scholar
  54. 54.
    Nguyen HN, Sevin BU, Averette HE et al (1993) Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines. Cancer Invest 11:264–275PubMedGoogle Scholar

Copyright information

© Feseo 2007

Authors and Affiliations

  • V. Cepero
    • 1
  • B. García-Serrelde
    • 1
  • V. Moneo
    • 1
  • F. Blanco
    • 1
  • A. M. González-Vadillo
    • 2
  • A. Álvarez-Valdés
    • 2
  • C. Navarro-Ranninger
    • 2
  • A. Carnero
    • 1
    Email author
  1. 1.Programa de Terapias ExperimentalesCentro Nacional de Investigaciones Oncológicas (CNIO)MadridSpain
  2. 2.Departamento de Química InorgánicaUniversidad Autónoma de MadridMadridSpain

Personalised recommendations